American Marconi Wireless News - Relief Therapeutics Publishes 2025 Annual General Meeting Agenda

David Walliams Identified as Celebrity in Sexual Misconduct Allegations After Legal Bid
Sherilyn Smith Encourages Women to Embrace Scars as Symbols of Resilience
Korea's Severe Asthma Patients Blocked from Biologics by Restrictive Reimbursement Rules
Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems
Shanghai Science and Technology Museum Signs Pacts With London and Ottawa Institutions at CIIE
Lytica Launches the DSX, the First Connected, Agentic System of Work for Direct-Material Sourcing of Electronic Components
SMX Develops AI-Powered Scientific Intelligence Platform to Accelerate Material Research and Expand Commercial Services
Opportunistic Trader ETF(WZRD) to Delist and Liquidate
LiveOne (Nasdaq: LVO) Releases Preliminary H1 Fiscal 2027 Results: $37.3 Million in Revenue and Record Audio Adjusted EBITDA* of $7.8 Million, Up 619% Year-Over-Year
Critics and Listeners Agree: Eylsia Nicolas' "The Wedding Song" Nominated for GlacerFM's Best Pop Song 2026; Second Consecutive Listener's Choice Nomination Follows Widespread Critical Recognition and Growing Global Audience

NYSE - LSE

RBGPF	0%	75.17	$
RIO	-1.5%	85.11	$
RELX	-0.7%	39.74	$
CMSC	-1.29%	20.2	$
RYCEF	2.23%	17.9	$
BCC	-3.41%	70.175	$
NGG	-0.67%	83.7	$
GSK	-0.38%	51.345	$
BTI	1.25%	60.85	$
BCE	0.74%	21.65	$
JRI	-1.27%	11.78	$
AZN	-1.65%	186.315	$
CMSD	-1.26%	20.225	$
VOD	-0.51%	15.61	$
BP	-1.44%	43.955	$

Relief Therapeutics Publishes 2025 Annual General Meeting Agenda

BOULEVARD 15.05.2025

GENEVA, SWITZERLAND / ACCESS Newswire / May 15, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published the agenda for its 2025 Annual General Meeting (AGM) of shareholders, to be held on June 12, 2025, at 10:00 a.m. CEST in Geneva, Switzerland.

Text size:

The agenda includes approval of the 2024 annual report and financial statements, appropriation of available earnings, discharge of the board of directors and executive committee, re-election of the members of the board of directors and its chairman, re-election of the members of the nomination and compensation committee, and approval of the maximum compensation amounts for the board of directors and executive committee. Also included are a consultative vote on the 2024 compensation report and the re-election of the independent voting rights representative and auditors.

The formal notice of convocation of the AGM, including information regarding attendance in person or by proxy, notification and registration requirements, and ancillary documents relevant to the meeting, will be mailed to registered shareholders on May 21, 2025. The full agenda is available on the Relief website .

ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com

CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
[email protected]

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: Relief Therapeutics Holding SA

View the original press release on ACCESS Newswire

F.Pedersen--AMWN

American Marconi Wireless News - Relief Therapeutics Publishes 2025 Annual General Meeting Agenda

Relief Therapeutics Publishes 2025 Annual General Meeting Agenda

Featured

David Walliams Identified as Celebrity in Sexual Misconduct Allegations After Legal Bid

Fast Finance Pay Corp Reports Third Quarter 2026 Financial Results and Provides a Business Update

Medical Care Technologies Inc. (OTCID:MDCE) Subsidiaries to Manage $20 Million in Private Collectibles Assets

Envision Pharma Group appoints Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian